News Feed Opinion Career Insight Dialogues Blog
Positive Societies Drugs Stories History
December, 2023
December 2023
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Yao Yu: Happy to share our work on Stereotactic radiosurgery with concurrent Antibody Drug Conjugates
Photo taken from Yao Yu/Twitter
Oct 31, 2023, 10:11

Yao Yu: Happy to share our work on Stereotactic radiosurgery with concurrent Antibody Drug Conjugates

Yao Yu, Radiation Oncologist at Memorial Sloan Kettering Cancer Center, shared on X/Twitter:

“Happy to share our work on Stereotactic radiosurgery (SRS) with concurrent Antibody Drug Conjugates (ADCs), now out in JAMA Oncology! In this study, led by Emily Lebow, we investigated the risk of symptomatic radiation necrosis for patients receiving SRS in brain metastases. ADCs included T-DXd (Trastuzumab deruxtecan), T-DM1 (Trastuzumab emtansine) and SG (Sacituzumab govitecan).

The study included 98 patients and 564 individual brain metastases treated at Memorial Sloan Kettering. We tracked information on brain metastasis volume, ADC timing, and all courses of prior and subsequent radiotherapy. Concurrent ADC was defined as ADC <= 3 weeks before SRS or < 1 week after SRS.

The overall risk of symptomatic radiation necrosis was 8.5% for the entire cohort, but concurrent ADC was associated with much higher risk (SHR 4.01) on univariable analysis. This risk was independent of volume (SHR 1.14 /cc) and prior RT (SHR 2.99).

The absolute risk of symptomatic radiation necrosis after SRS and concurrent ADC was low for small brain metastases, but increased rapidly with volume. Similar effects were observed across ADCs.

Image

We hope teams treating brain metastases will find this useful when counseling and selecting patients for SRS. More to come from our team!”

For the article click here.
Source: Yao Yu/Twitter

 

Antibody drug conjugates cancer Emily Lebow JAMA Oncology Memorial Sloan Kettering Cancer Center OncoDaily Oncology stereotactic radiosurgery Yao Yu
Blog
Dec 10, 2023, 19:32
Tomain Murphy: We celebrated a colossal milestone with the delivery of the proton accelerator
Blog
Dec 10, 2023, 19:19
Wafik S. El-Deiry: I am super excited to be able to share guest editorial in The Cancer Letter with the vision for the Worldwide Innovative Network WIN Consortium in cancer personalized medicine
Blog
Dec 10, 2023, 19:10
Margaret Foti: We are proud to work with our partners to help this critical symposium grow and thrive
Blog
Dec 10, 2023, 18:16
Jérôme Salomon: World Health Organization is also releasing a technical manual on alcohol tax policy and administration
Insight
Dec 10, 2023, 18:12
The Cancer Research Interns (CRI) Summer Program is now accepting applications! - Train at NCI
Insight
Dec 10, 2023, 18:08
Apply for the Basic Research in Cancer Health Disparities Program - NCI Center to Reduce Cancer Health Disparities (CRCHD)
Blog
Dec 10, 2023, 18:07
Nathan Vardi: I traveled down to Maryland and spent the day at the FDA
Insight
Dec 10, 2023, 18:01
Giselle Sholler: Our research that led to the FDA-Oncologic Drugs Advisory Committee 70% approval for moving Difluoromethylornithine forward
Blog
Dec 10, 2023, 17:54
Christian Rutzer: Roche and Novartis - Basel's Research and Innovation Powerhouses
Blog
Dec 10, 2023, 17:48
Nick Vitanza: It's been a dream to bring better treatments to kids with DIPG and CNS tumors
Career
Dec 10, 2023, 17:39
Dr. Salami is the winner of the American Urological Association’s prestigious Gold Cystoscope Award - YUO
Blog
Dec 10, 2023, 17:32
Wafik S. El-Deiry: I wore my chemistry tie today in honor of your visit to Providence and Brown University
Insight
Positive
Societies
Career